¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple sleep latency test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • anticholinesterase test
    Ç×Äݸ°¿¡½ºÅ×¶ó¾ÆÁ¦°Ë»ç
  • antiglobulin test
    Çױ۷κҸ°°Ë»ç
  • antimicrobial susceptibility test
    Ç×±ÕÁ¦°¨¼ö¼º°Ë»ç
  • antinuclear antibody test
    Ç×ÇÙÇ×ü°Ë»ç
  • aptitude test
    Àû¼º°Ë»ç
  • articulation test
    ¹ßÀ½°Ë»ç
  • association test
    ¿¬»ó°Ë»ç
  • achievement test
    ¼ºÃëµµ°Ë»ç
  • autohemolysis test
    ÀÚ°¡¿ëÇ÷°Ë»ç
  • acid challenge test
    »êÅõ¿©°Ë»ç
  • acid elution slide test
    »ê¿ëÃâ½½¶óÀ̵å°Ë»ç
  • adsorption test
    ÈíÂø½ÃÇè, ºÎÂø°Ë»ç
  • afterimage test
    ÀÜ»ó°Ë»ç
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • paroxysmal sleep
    (¢¡narcolepsy) ¹ßÀÛ¼ö¸é, ±â¸éÁõ
  • phase-advanced sleep
    À§»óÀüÁø¼ö¸é
  • phase-delayed sleep
    À§»óÁö¿¬¼ö¸é
  • prolonged sleep
    Áö¼Ó¼ö¸é
  • prolonged sleep therapy
    ¼ö¸é¿¬ÀåÄ¡·á
  • REM sleep
    ºü¸¥´«¿îµ¿¼ö¸é
  • rhythm inversion sleep
    ¼ö¸é¸®µë¿ªÀü
  • sleep position restriction
    ¼ö¸éÀÚ¼¼Á¦ÇÑ
  • sleep
    Àá, ¼ö¸é
  • sleep seizure
    ¼ö¸é¹ßÀÛ
  • sleep spindle
    ¼ö¸é¹æÃß
  • sleep walking
    ¸ùÀ¯º´
  • sleep apnea syndrome
    ¼ö¸é¹«È£ÈíÁõÈıº
  • sleep choking syndrome
    ¼ö¸éÁú½ÄÁõÈıº
  • sleep-promoting substance
    ¼ö¸éÁõÁø¹°Áú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • HIT= hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • Ham test
    ÇܽÃÇè
  • Hams test
    Çܰ˻ç
  • Hearing test
    û·ÂÅ×½ºÆ®
  • HemoQuant test
    Çì¸ðÄöÆ®½ÃÇè
  • Henry fructose test
    Ç°ú´ç°Ë»ç
  • Hickey Hare test
    È÷Ű-Çì¾î½ÃÇè.
  • Hirschberg test
    È÷¸£½¬¹ö±×°Ë»ç
  • Histalog test
    È÷½ºÅ»·Î±×½ÃÇè
  • Hoesch test
    Èѽ´½ÃÇè
  • House-Tree-Person Test
    Áý-³ª¹«-»ç¶÷ °Ë»ç
  • Jones dye test
    ÁÔ½º»ö¼ÒÀ¯Ãâ°Ë»ç
  • Kahns test
    Ä­ ¸Åµ¶Ç÷û°Ë»ç
  • Kerry reducing substance test
    Äɸ®È¯¿ø¹°Áú½ÃÇè
  • Kinberg s test
    Ųº£¸£Å©°Ë»ç(¡­ËþÞÛ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • syndrome, obstructive sleep apnea
    Æó¼â¼º ¼ö¸é¹«È£ÈíÁõÈıº
  • syndrome, sleep apnea
    ¼ö¸é¹«È£ÈíÁõÈıº
  • twilight anesthesia =t. sleep
    ¹Ý¸¶Ãë»óÅÂ(ÚâØ«ö­ßÒ÷¾).
  • twilight sleep
    ¹Ý¸¶Ãë»óÅÂ(ÚâØ«ö­ßÒ÷¾).
  • winter sleep
    µ¿¸é(ÔÏØù).
  • acidified serum test=Ham test
    »ê¼ºÈ­Ç÷û°Ë»ç
  • acidified-serum lysis test=Ham test
    »ê¼ºÈ­Ç÷û¿ëÇ÷°Ë»ç
  • antiglobulin test = Coombs test
    Çױ۷κҸ°°Ë»ç
  • biologic test ; biological test
    »ý¹°ÇÐÀû ½ÃÇè(¡­ãËúÐ).
  • bromosulfalein test =BSF test
    ºê·Ò¼úÆÛ·¹ÀνÃÇè.
  • difference limen test =DL test
    ÆÇº°¿ªÄ¡°Ë»ç
  • extinction test ; blanching test
    ¼Ò¸ê½ÃÇè.
  • low-ionic-strength salt solution TEST = LISS test
    ÀúÀ̿°­µµ¿°¿ë¾×
  • lupus erythematosus test = LE test
    È«¹Ý¼º ·çǪ½º½ÃÇè(¡­ãËúÐ)
  • polyethylene glycol test =PEG test
    Æú¸®¿¡Æ¿·»±Û¸®Äݰ˻ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
MLAEP middle latency auditory evoked potential
MLR mean length response; middle latency response; mixed lymphocyte reaction
MLT left mentotransverse [fetal position] [Lat. mento-laeva transversa]; mean latency time; median letha...
PML peripheral motor latency; polymorphonuclear leukocyte; posterior mitral leaflet; progressive multifo...
SL sarcolemma; sclerosing leukoencephalopathy; secondary leukemia; segment length; sensation level; sen...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
OSA Obstructive Sleep Apnea
OSAS Obstructive Sleep Apnea Syndrome
OSAHS Obstructive sleep apnea hypopnea syndrome
PS Paradoxical Sleep
PSD Paradoxical sleep deprivation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antiglobulin test
    Çױ۷κθ° °Ë»ç, Çױ۷κθ° ½ÃÇè
    ºÒ¿ÏÀü Ç×ü°¡ ÀûÇ÷±¸¿Í °áÇÕÇϸ鼭 ºñÀÀÁý¼ºÀÎ °æ¿ì, ŸÁ¾ µ¿¹°¿¡¼­ ÀÛ¼ºÇÑ Ç× IgG Ç×ü¸¦ Ãß°¡ÇÔÀ¸·Î½á ´Ù¸®°¡ ³õ¾ÆÁ® ÀÀÁý¹ÝÀÀÀÌ ¹ß»ýÇÑ´Ù. 1945³â Coombs¿¡ ÀÇÇÏ¿© Àç¹ß°ßµÈ ¹æ¹ýÀÌ¸ç »ýü ³»¿¡¼­ ÀÌ¹Ì ÀûÇ÷±¸¿Í °áÇÕÇϰí ÀÖ´Â Ç×ü¸¦ °ËÃâÇÏ´Â Á÷Á¢ ½ÃÇè°ú À¯¸®ÇØ ÀÖ´Â Ç×ü¸¦ ÀûÇ÷±¸¿Í °áÇÕ½ÃŰ°í ³ª¼­ °ËÃâÇÏ´Â °£Á¢ ½ÃÇèÀÌ ÀÖ´Ù.
  • apomorphine test
    ¾ÆÆ÷¸ð¸£ÇÉ ½ÃÇè
  • Apt test
    ¾ÐÆ® ½ÃÇè
  • arginine-insulin test
    ¾Æ¸£±â´Ñ-Àν¶¸° ½ÃÇè
  • arm to lung time test
    ÆÈ Æó ¼øÈ¯ ½Ã°£ ½ÃÇè
  • Army General Classification test
    À°±º¼º ºÐ·ù ½ÃÇè
  • arylsulfatase test
    ¾Æ¸±¼³ÆÄÅ×À̽º ½ÃÇè
  • Aschheim-Zondek test
    ¾Æ½¬ÇÏÀÓ-Á¸µ¦ ½ÃÇè
  • ascorbate cyanide test
    ¾Æ½ºÄÚ¸£ºó»ê ½Ã¾ÈÈ­¹° ½ÃÇè
  • augmented histamine test
    °­È­ È÷½ºÅ¸¹Î Áõ°­ ½ÃÇè
    12½Ã°£ ´Ü½Ä ÈÄ¿¡ ÀÜ·ù À§ ³»¿ë¹°À» ÈíÃâ±â·Î »¡¾Æ³½ ÈÄ, 15ºÐ °£°ÝÀ¸·Î 1½Ã°£ µ¿¾È ±âÃÊ À§ ºÐºñ¾×À» äÃëÇÑ´Ù. äÃë¿Ï·á 30ºÐ Àü¿¡ Àû´ç·®ÀÇ Ç×È÷½ºÅ¸¹ÎÀ» ±ÙÀ° ³»¿¡ Åõ¿©ÇÑ´Ù. ±âÃÊ ºÐºñ äÃë°¡ ³¡³¯ ¶§ »ê¼º Àλê È÷½ºÅ¸¹ÎÀ» ÆÄÇÏÁÖ»çÇϰí, À§ ³»¿ë¹°À» 15ºÐ °£°ÝÀ¸·Î 1½Ã°£ µ¿¾È äÃëÇÑ´Ù. °¢ 15ºÐ°£ÀÇ Ç¥º»¹°¿¡ ´ëÇÑ ºÎÇÇ,
  • automated reagin test
    ÀÚµ¿È­ ¸®¾ÆÁø ½ÃÇè
  • Ayer's test
    ¿¡ÀÌ¾î ½ÃÇè
  • Babinski-Weil test
    ¹Ùºó½ºÅ°-¿ÍÀÏ ½ÃÇè
  • Bacitracin differential disk test
    ¹Ù½ÃÆ®¶ó½Å °¨º°ÆÇ ½ÃÇè, ¹Ù½ÃÆ®¶ó½Å °¨º° ¿øÆÇ ½ÃÇè
  • bacteriolytic test
    ¿ë±Õ ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
multiple stain <technique> A mixture of several dyes each having an independent selective action on one or more portions of the tissue.
(05 Mar 2000)
multiple sulfatase deficiency An inherited disorder (autosomal recessive) in which there is a failure to hydrolyze sulfatides and sulfated mucopolysaccharides; this failure leads to their accumulation in neural and extraneural tissues causing demyelination, sulfatiduria, facial and skeletal dysmorphism, etc.
(05 Mar 2000)
multiple symmetric lipomatosis Accumulation and progressive enlargement of collections of adipose tissue in the subcutaneous tissue of the head, neck, upper trunk, and upper portions of the upper extremities; seen primarily in adult males and of unknown cause.
Synonym: Launois-Bensaude syndrome, Madelung's disease, symmetric adenolipomatosis.
(05 Mar 2000)
multiple system atrophy A name grouping together the four cerebral degenerative diseases of olivopontocerebellar atrophy, shy-drager syndrome, striatonigral degeneration, and one form of parkinson disease, considering them different forms of the same disease process.
(12 Dec 1998)
multiple trauma Physical insults or injuries occurring simultaneously in several parts of the body.
(12 Dec 1998)
multiple vision polyopia
hamartoma syndrome, multiple A hereditary disease characterised by multiple ectodermal, mesodermal, and endodermal nevoid and neoplastic anomalies. Papules of the face and oral mucosa are the most characteristic lesion. Other changes occur in the skin, in the thyroid, the breast, the gastrointestinal system, and the nervous system.
(12 Dec 1998)
pregnancy, multiple The condition of bearing two or more foetuses simultaneously.
(12 Dec 1998)
hereditary multiple exostoses A disturbance of enchondral bone growth in which multiple, generally benign osteochondromas of long bones appear during childhood, commonly with shortening of the radius and fibula; the ill-effects are usually mechanical but malignant change is rare; autosomal dominant inheritance.
Synonym: diaphysial aclasis, hereditary deforming chondrodystrophy, multiple exostosis, osteochondromatosis.
(05 Mar 2000)
hereditary multiple trichoepithelioma <tumour> Multiple small benign nodules, occurring mostly on the skin of the face, derived from basal cells of hair follicles enclosing small keratin cysts; frequent autosomal dominant inheritance.
Synonym: acanthoma adenoides cysticum, Brooke's tumour, epithelioma adenoides cysticum, hereditary multiple trichoepithelioma.
Origin: tricho-+ epithelioma
(05 Mar 2000)
sclerosis, multiple The National Multiple Sclerosis Society says of ms that it is a disease that randomly attacks your central nervous system, wearing away the control you have over your body. Symptoms may range from numbness to paralysis and blindness. The progress, severity and specific symptoms cannot be foreseen. You never know when attacks will occur, how long they will last, or how severe they will be. most people are diagnosed with ms between the ages of 20 and 40. In medical terms, ms involves demyelinization of the white matter sometimes extending into the gray matter. Demyelinization is loss of myelin, the coating of nerve fibres composed of lipids (fats) and protein that serves as insulation and permits efficient nerve fibre conduction. The white matter is the part of the brain which contains myelinated nerve fibres and appears white, whereas the gray matter is the cortex of the brain which contains nerve cell bodies and appears gray. When myelin is damaged in ms, nerve fibre conduction is faulty or absent. Impaired bodily functions or altered sensations associated with those demyelinated nerve fibres give rise to the symptoms of ms. Recent research (1998) has also identified nerve cell death as part of the nervous system injury in ms.
(12 Dec 1998)
psychotherapy, multiple The use of more than one therapist at one time in individual or group psychotherapy.
(12 Dec 1998)
neoplasms, multiple primary Two or more abnormal growths of tissue occurring simultaneously. The neoplasms are histologically different and may be found in the same or different sites.
(12 Dec 1998)
drug resistance, multiple Simultaneous resistance to a broad spectrum of structurally and functionally distinct drugs following exposure to a single agent. It is thought to result from the overexpression of genes encoding an integral plasma membrane protein, p-glycoprotein.
(12 Dec 1998)
exostoses, multiple hereditary Hereditary disorder transmitted by an autosomal dominant gene and characterised by multiple exostoses (multiple osteochondromas) near the ends of long bones. The genetic abnormality results in a defect in the osteoclastic activity at the metaphyseal ends of the bone during the remodeling process in childhood or early adolescence. The metaphyses develop benign, bony outgrowths often capped by cartilage. A small number undergo neoplastic transformation.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á